Trial Profile
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs Programmed cellular immunotherapeutic (Primary)
- Indications Cytomegalovirus infections; Graft-versus-host disease
- Focus Adverse reactions; First in man
- Acronyms PROTECT
- Sponsors Fate Therapeutics
- 15 Aug 2022 Status changed from active, no longer recruiting to completed.
- 05 May 2021 Primary endpoint has not been met (Number of patients that experience Grades II-IV acute Graft vs Host Disease (aGvHD)), according to a Fate Therapeutics media release.
- 04 Mar 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.